摘要
目的 :研究体外构建的HSP70 肝癌抗原肽复合物诱导针对肝癌的特异性免疫反应能力 ,为该复合物的临床应用奠定基础。方法 :在体外构建HSP70 肝癌抗原肽复合物 ,联合应用粒 /巨细胞集落刺激因子 (GM CSF)及白介素 4 (IL 4 )直接从志愿者外周血中培养出DC ;以HSP70、HSP70 肝癌抗原肽、抗原肽分别刺激DC ,DC激活同源的T淋巴细胞产生细胞毒性T淋巴细胞 (CTL) ,检测其杀伤T2细胞和肝癌细胞系的能力。结果 :HSP70 抗原肽、抗原肽均可诱导CD8+的抗原肽特异性CTL ,而前者的诱导效果更强。结论 :体外构建的HSP70 抗原肽复合物具有免疫原性 ,HSP70可以增强抗原肽诱导特异性免疫反应的能力 ,HSP70
Objective:To explore the possibility of inducing cell mediated immune response with HSP70 antigenic peptide complex in vitro.Methods:HSP70 peptide complex was reconstituted in vitro.Granulocyte/macrophage colony stimulating factors and interleukin 4 were used to cultivate DC from peripheral blood of HLA A2 positive healthy donors.HSP70,HSP70 peptide complex or peptide was used to activate the DC individually,which will initiate homogenize T lymphocyte to form cytotoxic T lymphocyte(CTL).The cytotxicity of the CTL was detected by MTT assay.Results:It was found that peptide specific CD8 + CTL responses were readily elicited by HSP70 peptide complex or peptide.The CTL response primed by HSP70 peptide complex was more potene than peptide alone.Conclusion:The results suggest that HSP70 peptide complex is immunogenic and HSP70 can lead to great efficient CTL response,antigenic peptides and HSP70 complex may be used as peptide vaccines for cancer immunotherapy.
出处
《中国免疫学杂志》
CAS
CSCD
北大核心
2001年第11期584-586,592,共4页
Chinese Journal of Immunology
基金
国家自然科学重点课题基金资助 (课题号 39830 42 0 )
